Abstracts tagged "comparative effectiveness"

Abstract Number: 0603 • ACR Convergence 2024
Superior Effectiveness and Comparable Drug Retention of Anti-TNF Therapy versus Anti-IL-17A in Ankylosing Spondylitis After First Anti-TNF Failure: A Propensity Score-Matched Analysis from the Czech ATTRA Registry
Jakub Závada¹, Jana Baranová², Karel Pavelka¹, Jiří Vencovský³, Pavel Horak⁴, Kateřina Kusalová² and Ladislav Šenolt³, and collaborators of the ATTRA registry, ¹Institute of Rheumatology and Charles University, Praha, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic
Background/Purpose: This study aims to compare the drug survival, effectiveness, and safety of anti-IL-17A and anti-TNF drugs in patients with Ankylosing Spondylitis (AS) following the…
Abstract Number: 0669 • ACR Convergence 2024
Efficacy of Belimumab in Systemic Lupus Erythematosus: A Single-Centre Retrospective Study
buddhika Jayaratna¹, Pasan Serasinghe², Louise Nel³, Sahil Jain³, Shrish Sangle², Begona Lopez¹, Giovanni Sanna², Michelle Fernando¹ and David DCruz⁴, ¹Guys & St Thomas NHS Foundation Trust, London, United Kingdom, ²Guys & St Thomas NHS Foundation Trust, London, England, United Kingdom, ³Guys and St Thomas' Hospital, London, United Kingdom, ⁴The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multi-system autoimmune rheumatic disorder. Despite therapeutic advances, managing SLE remains challenging due to its complex pathogenesis and…
Abstract Number: 0748 • ACR Convergence 2024
Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica
Sebastian E. Sattui¹, Christian Dejaco², Kerri Ford³, Stefano Fiore⁴, Sebastian Unizony⁵, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹University of Pittsburgh, Pittsburgh, PA, ²Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Massachusetts General Hospital, Winchester, MA, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Treatment of polymyalgia rheumatica (PMR) is hindered by lack of glucocorticoid (GC)-sparing therapies with proven efficacy. A retrospective study showed a higher proportion of…
Abstract Number: 1193 • ACR Convergence 2024
Ultrasound-Guided Corticosteroid Injection versus Iontophoresis in Rhizarthrosis: A Prospective Comparative Multicentric Study
Olga Rusinovich¹, Andrea Liso Andrino², Maria Concepcion Sanchez³, Pilar Navarro Alonso⁴, Miguel Cantalejo Moreira⁵, ALBERTO DIAZ OCA⁴, Pablo Navarro Palomo⁶, Maria Machattou⁷, Maria Alonso de Francisco³, Carlota Navarro Joven⁸, Alejandro Martinez Rodado³, laura Ramos Ortiz de Zarate⁹, hildegarda Godoy Tundidor¹⁰, Maria Carmen Barbadillo Mateos⁷, Blanca Garcia-Magallon⁷, Jose Campos⁷, Mónica Fernández Castro¹¹, JESUS SANZ SANZ⁶ and Jose Luis Andreu⁶, ¹Hospital Universitario Puerta de Hierro Majadahonda., Boadilla del Monte, Spain, ²Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Majadahonda, Madrid, Spain, ³Puerta de Hierro Majadahonda University Hospital, Majadahonda, Spain, ⁴Fuenlabrada University Hospital, Fuenlabrada, Spain, ⁵Hospital Universitario de Fuenlabrada, Fuenlabrada. Madrid, Spain, ⁶Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain, ⁷Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, ⁸Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, ⁹Puerta de Hierro Majadahonda University Hospital, Majahonda, Spain, ¹⁰Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, ¹¹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Madrid, Spain
Background/Purpose: Trapeziometacarpal osteoarthritis is a common degenerative disease that causes pain and thumb dysfunction. It affects 16-25% of the population, mainly middle-aged women. Treatment modalities…
Abstract Number: 1306 • ACR Convergence 2024
A Comparative Analysis of ChatGPT-4, Microsoft’s Bing and Google’s Bard at Answering Rheumatology Clinical Questions
Pitchaporn Yingchoncharoen¹, Nattanicha Chaisrimaneepan², watsachon Pangkanon¹ and Jerapas Thongpiya¹, ¹Texas Tech Health Sciences Center, Lubbock, TX, ²Texas Tech University Health Sciences Center, Lubbock, TX
Background/Purpose: The role of artificial intelligence (AI) is rapidly expanding in medical fields, with an increased frequency of use by both patients and providers. There…
Abstract Number: 1362 • ACR Convergence 2024
Comparative Effectiveness of Upadacitinib versus Other JAK Inhibitors in Patients with Rheumatoid Arthritis in a Global Real-World Setting
Peter C. Taylor¹, Aditi Kadakia², Jack Milligan³, Sander Strengholt², Oliver Howell³, Pankaj Patel², Sophie Barlow³ and Roberto Caporali⁴, ¹University of Oxford, Oxford, United Kingdom, ²AbbVie Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom, ⁴Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy
Background/Purpose: Network meta-analyses of phase 3 clinical trial data involving JAK inhibitor (JAKi)-treated patients with RA and an inadequate response to conventional synthetic DMARDs showed…
Abstract Number: 1534 • ACR Convergence 2024
Use and Safety of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients with Lupus Nephritis and Clinical Indications
April Jorge¹, Kila Panchot², Baijun Zhou², Aakash Patel¹ and Hyon K. Choi³, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have nephroprotective and cardioprotective benefits and may have a role in lupus nephritis (LN) treatment. 2023 EULAR SLE treatment guidelines…
Abstract Number: 2021 • ACR Convergence 2024
The Dual Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Nephrolithiasis and Gout Flares Among Gout Patients with Type 2 Diabetes: New User, Active Comparator Target Trial Emulation Studies
Natalie McCormick¹, Chio Yokose², Leo Lu³, Deborah Wexler¹, J. Antonio Avina-Zubieta⁴, Mary A. De Vera⁵, saiajay chigurupati¹, Kiara Tan¹, Chixiang Chen⁶, Rozalina McCoy⁶, Gary Curhan⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁵University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ⁶University of Maryland, School of Medicine, Baltimore, MD, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Massachusetts General Hospital, Lexington, MA
Background/Purpose: Nephrolithiasis and gout are both common, extremely painful conditions which frequently coexist, along with type 2 diabetes (T2D). Sodium-glucose cotransporter-2 inhibitors (SGLT2i), first approved…
Abstract Number: 2022 • ACR Convergence 2024
Could Initiation of Sodium Glucose Co-Transporter-2 Inhibitors Reduce the Need for Conventional Urate-Lowering Therapy and Flare Medications in Patients with Gout?Population-Based Target Trial Emulation Studies
Natalie McCormick¹, Chio Yokose², Leo Lu³, Sharan Rai¹, Gregory Challener¹ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate levels and are associated with reduced risk of incident gout as well as recurrent flares [Annals IM…
Abstract Number: 2008 • ACR Convergence 2023
Comparative Effectiveness of Denosumab versus Alendronate Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Jeffrey Curtis¹, Tarun Arora², Ye Liu¹, Tzu-Chieh Lin³, Leslie Spangler³, Vanessa C. Brunetti³, Robert K. Stad³, Michele McDermott³, Brian D. Bradbury³ and Min Kim³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, ³Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than oral bisphosphonates, evidence is lacking…
Abstract Number: 2412 • ACR Convergence 2023
Evaluation of the Pretest Probability Score, Ultrasound and Biopsy on GCA Diagnose: Data from Real Clinical Practice
María del Carmen San José Méndez¹, Uxía Couto Lareo¹, Vanesa Balboa Barreiro², Francisco J. Blanco¹, Bruno de aspe de la iglesia¹, Antonio Atanes Sandoval³, Diego Dios Santos¹, Jesús Carlos Fernández López¹, Mercedes Freire González¹, Guillermo González Arribas¹, Genaro Graña Gil¹, Natividad Oreiro Villar¹, Jose Antonio Pinto Tasende¹, Francisco Javier De Toro Santos¹, Clara Ventin Rodriguez¹, Maite silva díaz³ and Ana Lois Iglesias¹, ¹Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ²Clinic epidemiology and biostatistics department. Complejo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ³Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain
Background/Purpose: Giant cell arteritis (GCA) affects large and medium size arteries. Biopsy was considered the gold standard in the diagnosis1, but in the last years…
Abstract Number: 2485 • ACR Convergence 2023
Comparative Risk of Serious Psychiatric Events with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus
April Jorge¹, Baijun Zhou¹, Yuqing Zhang² and Hyon K. Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: In randomized placebo-controlled trials, including the phase 4 Belimumab Assessment of Safety in SLE study, belimumab use was associated with a higher incidence of…
Abstract Number: 0155 • ACR Convergence 2023
Cost Analysis of Subcutaneous Methotrexate Compared to Oral Methotrexate Treatment for Rheumatoid Arthritis
Aniket Kawatkar, David Yi, Erika Estrada and Cecilia Portugal, Kaiser Permanente Southern California, Pasadena, CA
Background/Purpose: Rheumatoid Arthritis (RA)patients who switch from oral to subcutaneous methotrexate (MTX) may experience better response to treatment due to increased bioavailability, enhanced tolerability, increased…
Abstract Number: 2529 • ACR Convergence 2023
Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Jeffrey R Curtis¹, Tarun Arora², Ye Liu³, Vanessa C. Brunetti⁴, Tzu-Chieh Lin⁴, Leslie Spangler⁴, Robert K. Stad⁴, Michele McDermott⁴, Brian D. Bradbury⁴ and Min Kim⁴, ¹Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than zoledronic acid (ZA), evidence from…
Abstract Number: 0199 • ACR Convergence 2023
Experience in Real-World Conditions of the Effectiveness of the Vaccine Against Herpes Zoster Virus
Laura Mas Sanchez¹, Pablo Francisco Muñoz Martínez², Elena Grau Garcia³, Alba Maria Torrat Noves³, Daniel Ramos Castro³, Carmen Riesco Barcena³, Anderson Victor Huaylla Quispe³, Belen Villanueva Mañez³, Iago Alcantara Alvarez³, Samuel Leal Rodriguez³, Marta De la Rubia Navarro¹, Ernesto Tovar Sugrañes³, Jose Ivorra Cortes³, Luis Gonzalez Puig³, Rosa Negueroles Albuixech³, Elvira Vicens Bernabeu³, Jose Eloy Oller Rodriguez³, Isabel Martinez Cordellat³, Hikmat Charia³, Ines Canovas Olmos³, Carmen Najera Herranz³ and Jose Andres Roman Ivorra⁴, ¹Rheumatology Department. HUP La Fe, Valéncia, Spain, ²Rheumatology Department. HUP La Fe, Sagunto, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Spain, ⁴Hospital Universitari i Politècnic la Fe, Valencia, Spain
Background/Purpose: Herpes zoster infection is due to the reactivation of the varicella-zoster virus (VZV), having a high prevalence in elderly and immunocompromised patients. Since the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].